Clinical trials: Aplastic Anaemia
Sickle Cell Disease, Thalassemia
Stem Cell Transplant for Hemoglobinopathy
This study tests the clinical outcomes of one of two preparative regimens (determined by available donor source) in patients with non-malignant hemoglobinopathies.
- Conditions
- Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia, Diamond-Blackfan Anemia
- Trial name
- NCT00176852
- Testing
- Busulfan, Fludarabine, ATG, TLI, Busulfan, Cyclophosphamide, ATG, GCSF, Campath, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Severe Aplastic Anemia
hATG+CsA vs hATG+CsA+Eltrombopag for SAA
The null hypothesis of no difference in CR% at 3 months between the arms will be tested against the alternative of a difference in CR% at an alpha level of .05 by assessing the odds ratio for arm yielded by this model.
- Trial name
- RACE (NCT02099747)
- Testing
- hATG, CsA, Eltrombopag
- Where
- 29 sites in France, Italy and 4 more
- Volunteers
- 202 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Severe Aplastic Anemia (SAA)
Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia
Severe aplastic anemia is a life-threatening bone marrow failure disorder. Haploidentical hematopoietic stem cell transplantation has become an important curative treatment option for patients who do not have an HLA-matched…
- Trial name
- PB-Graft Haplo (NCT07629947)
- Testing
- G-CSF-Primed Peripheral Blood Stem Cell Graft, G-CSF-Primed Bone Marrow Plus Peripheral Blood Stem Cell Graft
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Peking University People's Hospital
Severe Aplastic Anemia (SAA)
Extended Dosing With Eltrombopag for Severe Aplastic Anemia
Background: Eltrombopag is a drug being tested for treating severe aplastic anemia. It can help improve blood counts in these patients.
- Trial name
- NCT01891994
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Aplastic Anemia
Prophylactic NAC to Improve Platelet Engraftment After Haploidentical Transplantation in Severe Aplastic Anemia Patients
This study aims to evaluate the efficacy and safety of prophylactic oral N-acetylcysteine (NAC) for facilitating platelet engraftment in patients with severe aplastic anemia (SAA) receiving haploidentical hematopoietic stem cell…
- Trial name
- NCT07737262
- Testing
- N-acetylcysteine
- Volunteers
- 142 people
- Sponsor
- Peking University People's Hospital
Thalassemia, Sickle Cell Disease
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic blood and marrow transplantation remains the only viable cure for children who suffer from many serious non-malignant hematological diseases. Transplantation, however, carries a high risk of fatal complications.
- Conditions
- Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome
- Trial name
- NCT01319851
- Testing
- Alefacept
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Anemia, Aplastic
Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia
Our hypothesis is that ex vivo activated immune cells would produce multiple known and unknown potent hematopoietic cytokines, working in concert, these cytokines help stem cell growth and differentiation.
- Trial name
- NCT00399971
- Testing
- Ex Vivo Immunotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Zhongxing Yangfan Biotech Co. Ltd.
Fanconi's Anemia, Pancytopenia
Gene Therapy for the Treatment of Fanconi's Anemia Type C
Fanconi's Anemia is an inherited disorder that can produce bone marrow failure. In addition, some patients with Fanconi's anemia have physical defects usually involving the skeleton and kidneys.
- Trial name
- NCT00001399
- Testing
- Transduced CD34+ Cells
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Advanced Cancers
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
This research study is studying a checkpoint kinase 1 (CHK1) inhibitor as a possible treatment for advanced solid tumors that harbor genetic alterations in the homologous repair (HR) pathway, genetic alterations that indicate…
- Trial name
- NCT02873975
- Testing
- LY2606368
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Lymphoma
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
The main purpose of this study is to assess the effects of cyclophosphamide (cytoxan) in the post transplant setting to prevent onset of acute graft-versus-host disease (GVHD).
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- NCT02065154
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Alabama at Birmingham
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Reduced Intensity Double Umbilical Cord Blood Transplantation
This trial will use two cord blood units for transplantation using a reduced intensity regimen rather than using intense doses of chemotherapy and radiation therapy.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01408563
- Testing
- Fludarabine, Melphalan, Total Body Radiation
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
Aplastic Anemia
Romiplostim N01 in Chemoradiotherapy-induced Aplastic Anemia
This study aimed to explore the efficacy and safety of romiplostim N01 in the treatment of chemoradiotherapy-induced aplastic anemia (AA)
- Trial name
- NCT07572084
- Testing
- Romiplostim N01
- Volunteers
- 43 people
- Sponsor
- Peking Union Medical College Hospital
Acute Leukemia, Myelodysplastic Syndromes
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
Graft-versus-host disease (GVHD) is an important complication after transplantation, with an incidence of 40-60%, which can increase non-relapse mortality if poorly controlled.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia
- Trial name
- NCT06279494
- Testing
- Sirolimus, Abatacept, MMF
- Volunteers
- 6 people
- Sponsor
- Peking University People's Hospital
Acute Leukemias, Aplastic Anemia
Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells
Feasibility and toxicity of haploidentical transplantation of CD3/CD19 depleted stem cells in combination with a toxicity reduced conditioning regimen or with standard conditioning regimens according to underlying disease.
- Conditions
- Acute Leukemias, Aplastic Anemia, Childhood Solid Tumor
- Trial name
- NCT01919866
- Testing
- Transplantation of CD3/CD19 depleted stem cells
- Where
- 5 sites in Austria, Germany
- Volunteers
- 120 people
- Sponsor
- University Children's Hospital Tuebingen
Aplastic Anemia
Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole
The clinical symptoms of non transfusion dependent non severe aplastic anemia (NSAA) are often lighter than that of severe aplastic anemia.
- Trial name
- NCT03218657
- Testing
- levamisole hydrochloride, Androgens, Cyclosporins
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Shengyun Lin
Aplastic Anemia
GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT
Objectives 2.1 Primary objectives 1) To observe and compare incidence and severity of aGVHD and cGVHD between the two arms within 2 years after transplantation. 2) To observe and compare the engraftment rate between the two arms.
- Trial name
- NCT05510505
- Testing
- CD20 monoclonal antibody, ATG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Aplastic Anemia, Refractory
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
This study consists of two phases, phase Ib and phase II. The primary objective of phase Ib is to evaluate the safety and tolerability of multiple doses of daratumumab in patients with refractory aplastic anemia.
- Conditions
- Aplastic Anemia, Refractory, Relapse
- Trial name
- DARA-AA-001 (NCT07287228)
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Aplastic Anemia
Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
RATIONALE: Immunosuppressive therapies, such as anti-thymocyte globulin and cyclosporine, may improve bone marrow function and increase blood cell counts.
- Trial name
- NCT01231841
- Testing
- cyclosporine, anti-thymocyte globulin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Cleveland Clinic
Severe Aplastic Anemia
Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia.
The study is a phase II trial designed to evaluate the efficacy and safety of co-transplantation with bone marrow derived mesenchymal stem cells from related donors in alternative donor transplantation of severe aplastic anemia.
- Trial name
- NCT02247973
- Testing
- mesenchymal stem cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangzhou General Hospital of Guangzhou Military Command
Severe Aplastic Anemia
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
- Trial name
- BMT CTN CureAA (NCT06517641)
- Testing
- Haploidentical donor bone marrow transplant, Unrelated donor bone marrow transplant
- Where
- 25 sites in United States
- Volunteers
- 60 people
- Sponsor
- Medical College of Wisconsin